MedTrace Logo

Safety Study of Olopatadine Nasal Spray

NCT00578331 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 890

Last updated 2017-10-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether olopatadine nasal spray is safe and effective when used for up to one year by patients with perennial allergic rhinitis.

Conditions

  • Perennial Allergic Rhinitis

Interventions

DRUG

Olopatadine 0.6% nasal spray

2 sprays each nostril twice daily

DRUG

Placebo Nasal Spray

2 sprays each nostril twice daily

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Margaret Drake · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00578331 on ClinicalTrials.gov